Rivastigmine Patent Expiration
Rivastigmine is Used for managing symptoms of Alzheimer's dementia. It was first introduced by Sandoz Inc
Rivastigmine Patents
Given below is the list of patents protecting Rivastigmine, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Exelon | US6316023 | TTS containing an antioxidant |
Jan 08, 2019
(Expired) | Sandoz |
| Exelon | US6335031 | TTS containing an antioxidant |
Jan 08, 2019
(Expired) | Sandoz |
| Exelon | US5602176 | Phenyl carbamate |
Feb 11, 2014
(Expired) | Sandoz |
| Exelon | US4948807 | Phenyl carbamates |
Aug 14, 2012
(Expired) | Sandoz |
Rivastigmine's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Rivastigmine:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Rivastigmine for Antimuscarinic Delirium | Washington University School of Medicine | NA |
RECRUITING
(Jun 1, 2026)
| PHASE2 |
| Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium | Washington University School of Medicine | NA |
SUSPENDED
(Jun 1, 2026)
| PHASE2 |